roBNP levels may be signs or symptoms of heart failure. If heart failure occurs, consider discontinuation of CAMZYOS or dose reduction. Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS.
Hypotension CAMZYOS can lower blood pressure. Assess the patient\’s clinical status and adjust antihypertensive therapy as needed during treatment with CAMZYOS.
Interactions with Cytochrome P450 Inhibitors and Inducers Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction. Avoid concomitant use of CAMZYOS with moderate to strong CYP2C19 inhibitors or strong CYP3A4 inhibitors, and moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers.
Adverse Reactions The most common adverse reactions (incidence ‰¥10%) were: chest pain, headaches, diarrhea, muscle spasms, and anemia.
Please see full Prescribing Information for CAMZYOS, including Boxed WARNING, at www.CAMZYOS.com.
About